1,720,967 research outputs found
Il ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: risultati di uno studio multicentrico retrospettivo.
No full textNon organo-specific autoantibodies in hepatitis C virus infection: a protective phenomenon?
No full text
LE VASCULITI: Aspetti generali. Arterite di Takayasu. Arterite gigantocellulare. Poliarterire nodosa. Malattia di Kawasaki. Granulomatosi di Wegener. Sindrome di Churg-Strauss. Poliangioite microscopica. Vasculiti da ipersensibilità. Vasculite crioglobulinemica. Malattia di Behcet. Altre vasculiti.
No full textCapitolo a carattere monografic
SCLERODERMIA
No full textIl classico termine sclerodermia, che etimologicamente-ed erroneamente-richiama l'attenzione soltanto sulle manifestazioni cutanee della malattia
Chronic hepatittis C virus infection: detection of hepatocellular carcinoma by means of contrast-enhanced color doppler liver sonography
No full textLong-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon
No full textA retrospective multicentre survey was conducted to evaluate, in patients with chronic hepatitis C, the long-term liver histological changes induced by interferon (IFN). A total of 112 patients (mean age 46.4 years) were studied. All patients had received a 6-12-month IFN-alpha course (6-18 MU/week) and had successively undergone clinical, biochemical and virological follow-up for at least 36 months (range: 36-76). In each patient, two liver biopsies had been performed: 1-6 months before treatment and, 12-76 months after its completion. In 87 patients with biochemical and virological sustained response persisting for 12 months after therapy, post-treatment liver necroinflammation and fibrosis mean(+/-SD) scores (Knodell index) were significantly lower than pretreatment scores (2.9 +/- 2.2 vs 6.8 +/- 2.9 and 0.8 +/- 1.0 vs 1.2 +/- 1.1, respectively; P 0.05). On an individual basis, necroinflammation decreased in 87% of sustained responders but only in 36% of relapsers (P < 0.001), whereas fibrosis decreased in 44% of sustained responders but only in 14% of relapsers (P < 0.001). In sustained responders with biopsies performed 12-23 months (n = 34), 24-35 months (n = 26) or more than 36 months (n = 27) after treatment, a progressive decrease of mean necroinflammatory score was observed (-2.6 +/- 2.1, -4.1 +/- 3.4 and -5.2 +/- 3.7 points, respectively; P < 0.01). A similar pattern was observed in fibrosis score (-0.3 +/- 0.6, -0.3 +/- 0.7 and -0.7 +/- 0.9 points, respectively; P < 0.05). Hence, among chronic hepatitis C patients treated with IFN, those with a 12-month sustained response, unlike those who relapse, have a long-term progressive reduction and, in some cases, a complete regression of liver histological damage
- …
